Litigation

Recent Posts

Abbott Withdraws Diet Pill Meridia In United States, Canada
Posted on 8 Oct 2010 by LexisNexis Litigation Resource Community Staff

WASHINGTON, D.C. — (AP) Abbott Laboratories said Friday it will withdraw its diet pill Meridia in the U.S. and Canada, after coming under pressure from health regulators who say the drug increases the risk of heart attack and stroke in patients... Read More

Tags: weight loss , Wyeth , Vivus Inc. , Dr. John Jenkins , Food and Drug Administration , Abbott Laboratories , diet drugs , diet pill , Meridia , FDA , fen-phen , Arena Pharmaceuticals , Litigation , lawsuit , Roche , Health Canada , Xenical , Qnexa

Watchdog Group Makes 2nd Push To Ban Diet Pill
Posted on 15 Apr 2011 by LexisNexis Litigation Resource Community Staff

WASHINGTON, D.C. - (AP) For the second time in five years, public health advocates are calling on the Food and Drug Administration to ban a fat-blocking drug sold over-the counter and via prescription, pointing to new reports of kidney stones and pancreatic... Read More

Tags: Pondimin , Wyeth , obesity , Food and Drug Administration , Darvon , Public Citizen , Alli , diet drugs , diet pill , Meridia , FDA , Orlistat , fen-phen , fenfluramine , Redux , Litigation , GlaxoSmithKline , Roche , Xenical

Abbott Withdraws Diet Drug Meridia From U.S. Market
Posted on 8 Oct 2010 by Tom Moylan

ABBOTT PARK, Ill. - (Mealey's) After an unfavorable assessment by a Food and Drug Administration expert committee regarding cardiovascular risk, Abbott Laboratories on Oct. 8 agreed with an FDA request to withdraw the weight-loss drug Meridia (sibutramine... Read More

Tags: sibutramine , weight loss , Sibutramine Cardiovascular Outcomes Trial , Steering Committee v. Abbott Laboratories , Center for Drug Evaluation and Research , Food and Drug Administration , Abbott Laboratories , diet drugs , SCOUT , Meridia , FDA , Office of New Drugs , Litigation , multidistrict litigation , Endocrinologic and Metabolic Drugs Committee , Meridia Products Liability Litigation , MDL , John Jenkins , black-box warning